Lessons

How to read a clinical trial result with discipline — the difference between absolute and relative risk reduction, what number-needed-to-treat captures, what confidence intervals actually mean, the hierarchy of evidence quality, and why statistical significance is not the same as clinical importance.

The phased structure of drug development from preclinical work through phase IV surveillance, what each phase actually establishes, the 90% attrition rate and where it lives, the difference between surrogate and hard clinical endpoints, and what regulatory approval pathways guarantee.

What the GLP-1 hormone does in normal physiology, why agonists of its receptor produce effects on glucose, gastric emptying, satiety, and weight, how peptide engineering achieves week-long duration, and what the clinical trial evidence shows beyond glycemic control.

How base editors convert one base to another by chemistry rather than by cutting, how prime editors use a programmable template and reverse transcription to make arbitrary small edits, and the structural trade-offs between scope, efficiency, and off-target activity.

How CRISPR/Cas9 cuts a specific DNA sequence using a programmable guide RNA, the two cellular repair pathways that determine whether the edit is a disruption or a correction, the structural problem of off-target effects, and what delivery into human cells actually requires.

The flow of information from DNA through mRNA to protein, what mutations actually change, why single-base changes can have outsized consequences, and the structural reason genome editing aims at DNA specifically.

The standard set of business-cycle indicators — leading, coincident, lagging — what each measures, the structural information content of the yield curve, the difference between NBER and technical recession definitions, and how to combine signals into a coherent cyclical picture.

How fiscal policy (taxation, spending, deficits) and monetary policy (rates, balance sheet) act on the economy through different channels, how they interact, what the debt-sustainability condition r < g implies, and where fiscal dominance constrains the central bank.

The conceptual difference between real and nominal quantities, how the Fisher equation links them, why real interest rates drive investment decisions while nominal rates appear in contracts, and the systematic mistakes that come from confusing the two.

The instruments a modern central bank uses to influence the economy — policy rate, open-market operations, reserve requirements, lender-of-last-resort facilities, quantitative easing, and forward guidance — and the transmission channels through which each affects inflation and employment.

How inflation is measured (CPI, PCE, GDP deflator), the demand-pull and cost-push mechanisms, why the modern Phillips curve depends on inflation expectations, and the structural reason 'anchored' expectations matter so much to outcomes.

The functional definition of money, the distinction between base money and broad money, how the banking system creates the latter from the former, and why the quantity equation (MV = PQ) relates money to prices only through variables that themselves move.

What cryptographic schemes Shor's algorithm threatens, what post-quantum schemes replace them, the math behind lattice-based cryptography, the NIST standardization process and its outputs, and the operational mechanics of a real-world cryptographic migration.

Shor, Grover, Hamiltonian simulation, HHL — the catalog of known quantum-algorithmic speedups, what 'speedup' precisely means in each case, and the structural reasons most problems do not gain exponential advantage.

Why classical error correction does not directly transfer to qubits, how stabilizer codes and syndrome measurement work around the no-cloning constraint, the surface code as the leading approach, and the math of physical-to-logical qubit overhead.

Six families of physical qubit implementations and the engineering trade-offs that distinguish them — coherence time, gate time and fidelity, scalability, and control complexity. The numbers behind 'which is best' depend on which metric you care about.

What entanglement is mathematically, how Bell states are built from Hadamard and CNOT, how quantum circuits compose, and why measurement on entangled subsystems looks correlated regardless of separation.

The mathematical object behind a qubit — a complex unit vector in a two-dimensional Hilbert space — and why measurement collapses superposition. The structural difference between a quantum state and a classical bit, expressed in math.

The geographic and corporate concentration of the chip supply chain expressed as engineering risk — single points of failure, the cost of redundancy, hedging strategies, and the customer-side concentration that mirrors the supply side. Structural analysis, not prediction.

The structural ingredients required to move a national or corporate semiconductor capability up the node ladder — capital, equipment access, process know-how, and talent — and the historical examples (Korea, Taiwan) of how earlier catchup campaigns played out.

How the US, Dutch, and Japanese export-control regimes for advanced semiconductors actually function — the legal instruments, the parameter thresholds in published regulations, the extraterritorial Foreign Direct Product Rule, and the licensing-and-enforcement mechanics.

Beyond lithography, a fab depends on etch, deposition, implantation, metrology, photoresist, wafers, and specialty gases. Each of these markets concentrated independently, and most show the same compounding-R&D pattern as lithography at smaller scale.

Why chip resolution is bounded by light wavelength, how the industry moved from 193 nm DUV to 13.5 nm EUV, and what makes lithography one of the most concentrated single-vendor markets in modern manufacturing.

The three business models in chip manufacturing — fabless designer, pure-play foundry, integrated device manufacturer — and the capex, yield, and learning-curve forces that drove the leading edge into a small handful of firms.